Medtronic plc the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy for patients with mild heart failure . This new analysis of the REVERSE clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently ...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new analysis of the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently published in the Journal of American College of Cardiology: Clinical Electrophysiology .

Heart failure impacts more than 6.5 million people in the U.S.; as a progressive disease, it worsens over time, leading to a reduced quality of life, greater risk of complications and death. CRT is an established treatment for select patients with heart failure and has been demonstrated to improve survival and quality of life and reduce heart failure-related hospitalizations.

"It is commonly stated within the cardiology community that about a third of patients do not respond to CRT," said Michael R. Gold , M.D., Ph.D., Michael E. Assey Professor of Medicine at the Medical University of South Carolina , Charleston. "However, REVERSE shows that with mild heart failure, patient stability is a long-term benefit of CRT, similar to patient improvement. Our current classifications do not give us the full picture of how patients benefit from CRT. We need to redefine our current understanding of CRT response to include stability as a favorable outcome for this patient population."

The progression of heart failure can be measured in a number of ways. Clinical Composite Score (CCS) is used to categorize patient outcomes as improved, unchanged (stabilized), or worsened, which is determined using clinical measures, heart failure status and patient symptoms. Similarly, left ventricular end systolic volume index (LVESVi) assesses the amount of blood remaining in the left ventricle after contracting to determine the heart's effectiveness at pumping blood to meet the body's needs. Since survival decreases as LVESVi rises, this measure has been shown to be an important predictor of long-term outcomes in patients.

Using the CCS (406 patients), more than half (56%) of patients with mild heart failure improved at one year, 30% remained unchanged (or stabilized), and 14% worsened; five-year mortality for improved or stabilized patients was 10% compared to 21% for worsened patients, p=0.01. Using the LVESVi measure (353 patients), there was a 73% decrease in the risk of dying at five years for CRT patients who stabilized or improved, compared to those whose condition worsened (i.e., five-year mortality for improved or stabilized patients was 8% compared to 30% for worsened patients, p

"As we look for innovative solutions to reduce the burden of heart failure, the REVERSE analysis underscores that our CRT devices provide benefits for a larger number of patients than we previously understood," said Rob Kowal , M.D., Ph.D., chief medical officer of Cardiac Rhythm Management, which is reported as part of the Cardiac and Vascular Group at Medtronic. "REVERSE reinforces the strong clinical evidence supporting CRT, and the value of CRT as an option to slow the progression of this debilitating disease. Time and again, the landmark CRT trials have demonstrated a range of patient stabilization or improvement with the application of cardiac resynchronization therapy."

Optimized Implementation of Cardiac Resynchronization Therapy: A Call for Action for Referral and Optimization of Care , a recent position statement issued by the European Society of Cardiology and its partners, similarly concluded that "a slowing of a progressive disease [such as heart failure] is a positive outcome," and "therefore 'stability' is seen as a positive outcome."

The REVERSE trial was the first, large scale, global, randomized, double-blind study to evaluate the benefits of CRT for patients with mild HF – those designated as New York Heart Association Class I/II. The trial included 73 sites worldwide, including those in the U.S. Western Europe , and Canada .

The Medtronic portfolio of therapies, diagnostic tools and services for patients suffering from heart failure includes CRT devices, including MR-conditional CRT-defibrillators and CRT-pacemakers; mechanical circulatory support therapy for advanced heart failure patients; heart failure diagnostics; and meaningful expert analysis through Medtronic Care Management Services.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:


Tracy McNulty

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-2492

+1-763-505-4626





Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/new-analysis-of-reverse-trial-reveals-benefits-of-crt-for-more-patients-with-heart-failure-301238152.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has secured a term loan commitment from TD Canada Trust for $3.2 million for the purpose of closing the Company's previously announced acquisition of three Ontario Diagnostic Imaging Clinics (Press release September 28, 2021).

Combined with the Company's cash on hand, the term loan will allow the Company to close the Ontario Diagnostic Imaging Clinics acquisition.

Keep reading... Show less
Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 13.1% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,244,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a non-exclusive, pilot supplier distribution agreement in Canada between HealthTab™ Inc., a wholly owned subsidiary, and Abbott, the global healthcare company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity.

The agreement allows HealthTab to distribute Abbott's point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function.

Keep reading... Show less

Medtronic Reports Second Quarter Fiscal 2022 Financial Results

- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021 .

Keep reading... Show less

Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development

Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby's health and development, including the developing immune system, digestive system and brain.

Abbott scientists have been studying HMOs in breast milk for more than two decades. While breast milk is the gold standard of infant nutrition, nearly 75% of parents introduce infant formula within the first six months of a baby's life for a variety of reasons. Abbott supports parents, whatever their feeding choice. Now with the introduction of Similac 360 Total Care, parents can use a formula with a blend of five specific HMOs, previously only available to infants through breast milk.

Keep reading... Show less

Top News

Related News